JPMorgan Asset Management Enters the Mass Tort Financing Spotlight

This move signals a fundamental shift: traditional litigation finance, which relied heavily on hedge funds and specialized boutiques, is now attracting...

This move signals a fundamental shift: traditional litigation finance, which relied heavily on hedge funds and specialized boutiques, is now attracting...

A firm starting in Kansas City or Milwaukee cannot instantly compete with established coastal firms, so successful ones identify high-volume tort...

A federal judge froze $5.6B in settlement proceeds after finding a law firm likely stole its funding partner's trade secrets.

California's wildfire compensation programs reveal how mass tort settlements can process tens of thousands of claims fairly and efficiently.

Mass tort cases take years to resolve, require no upfront costs, and limit your attorney's fee to 25–40% of recovery plus expenses deducted from your settlement.

Record settlement volumes and emerging product categories are forcing courts and litigants to navigate unprecedented complexity in mass tort litigation.

199,000 pending drug and device cases with $50+ billion at stake are forcing courts and manufacturers to confront mass tort litigation on an unprecedented scale.

Syngenta's second venue motion targets 1,600+ Pennsylvania paraquat claims in Philadelphia, repeating arguments a judge already rejected in 2025.

A Hofstra Law professor argues that proposed Roundup settlement discounts overstate the impact of pending Supreme Court uncertainty on claimants' remaining legal claims.

Bankruptcy courts, once backwater venues, now determine how millions in injury settlements are distributed—and claimants increasingly lose.